Exelixis Inc. (EXEL)
NASDAQ: EXELHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
EXEL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $14.48B
- P/E (TTM)
- 18.44
- Forward P/E
- 13.78
- EPS (TTM)
- $3.17
- Dividend yield
- None
- 52-week range
- 33.76 – 61.14
- Day range
- 57.89 – 59.27
- Volume / Avg
- 2.37M / 2.33M
- Beta
- —
- Shares outstanding
- 247.78M
- Next earnings
- Nov 3, 2026
52-week range
EXEL stock today
Shares of Exelixis (EXEL) finished higher on Oct 7 at $58.44, a gain of 0.19% or $0.11 per share, versus the S&P 500's 0.22% decline. At this level, EXEL sits near the top of its 52-week range of $33.76 to $61.14: 4.4% below the high, set on Sep 30, 2026 and 73.1% above the low. EXEL is up 33.3% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 47.5%.
At 18.4x trailing earnings, Exelixis trades below the peer-group median of 40.7x. Its forward P/E of 13.8x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Exelixis's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Exelixis
Company profileExelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Michael M. Morrissey Ph.D.
- Headquarters
- Alameda, CA
- Employees
- 1,077
- IPO year
- 2000
- Website
- exelixis.com
Financial highlights
Full financialsIn fiscal 2025, Exelixis generated $2.32 billion in revenue, up 7.0% from fiscal 2024, its 9th consecutive year of revenue growth. Net income was $782.6 million (+50.1% year over year), for a net margin of 33.7% versus a median of 11.4% in the prior 5 years. Gross margin was 96.4% (down from 96.5%) and operating margin 37.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B |
| Growth | +6.98% | +18.49% | +13.60% | +12.27% | +45.31% |
| Net income | $782.57M | $521.27M | $207.76M | $182.28M | $231.06M |
| EPS (diluted) | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 |
Analyst forecast
ForecastConsensus (18 analysts)
buy
Avg. price target
$54.53-6.69%
- Strong buy 1
- Buy 6
- Hold 10
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $0.79
- Last reported (Q2 2026)
- Aug 5, 2026
- EPS actual vs est.
- $0.82 vs —
Exelixis peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NBIXNeurocrine Biosciences Inc. | 143.47 | -1.40% | $14.58B | vs EXEL |
| HALOHalozyme Therapeutics Inc. | 110.79 | +0.98% | $12.57B | vs EXEL |
| TECHBio-Techne Corp | 72.53 | +0.14% | $11.37B | vs EXEL |
| RGENRepligen Corporation | 167.22 | -4.37% | $10.62B | vs EXEL |
| IBRXImmunityBio Inc. | 9.75 | +0.62% | $10.33B | vs EXEL |
| TWSTTwist Bioscience Corporation | 155.65 | -6.78% | $10.32B | vs EXEL |
| PCVXVaxcyte Inc. | 66.96 | +0.39% | $9.96B | vs EXEL |
| KRYSKrystal Biotech Inc. | 324.57 | -0.69% | $9.61B | vs EXEL |
Indexes, lists and sector
Exelixis stock FAQ
What is Exelixis's stock price today?
EXEL last traded at $58.44 as of Oct 7, 4:00 PM EDT, up 0.19% on the day. Prices are delayed at least 15 minutes.
When is Exelixis's next earnings date?
Exelixis is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $0.79.
What is EXEL's P/E ratio?
EXEL trades at a trailing P/E ratio of 18.44 and a forward P/E of 13.78, compared with a median of 40.7 for its closest peers.
Who is Exelixis's CEO?
Dr. Michael M. Morrissey Ph.D. is the chief executive officer of Exelixis Inc., which has about 1,077 employees.
What is the EXEL 52-week high?
The 52-week high for EXEL is $61.14 and the 52-week low is $33.76. The stock is currently 4.4% below its high.